ISRCTN46099817终止1 期
A phase I, open-label, single-dose study in male and female healthy subjects to assess the safety and pharmacokinetics of IV NEPA administered as IV bolus versus 30-minute IV infusion
Helsinn (Switzerland)0 个研究点目标入组 64 人开始时间: 2021年2月26日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 64
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Signed written informed consent before inclusion in the study
- •2. Aged 18 and 55 years
- •3. Body Mass Index (BMI) between 18.5 and 30 kg/m2
- •4. Vital signs, measured after 5 min at rest in the sitting position:
- •4.1. Systolic blood pressure between 100 and 139 mmHg
- •4.2. Diastolic blood pressure between 50 and 89 mmHg
- •4.3. Pulse rate between 50 and 90 bpm
- •5. Able to comprehend the full nature and purpose of the study, including possible risks and side effects, and able to co-operate with the Investigator and to comply with the requirements of the entire study
- •6. Women of child-bearing potential must have a negative pregnancy test result at screening and admission (Day -1) and be using at least one of the following reliable methods of contraception:
- •6.1. Hormonal oral, implantable, transdermal, or injectable contraceptives for at least 2 months before the screening visit
- •6.2. A non-hormonal intrauterine device [IUD] or female condom with spermicide or contraceptive sponge with spermicide or diaphragm with spermicide or cervical cap with spermicide for =2 months before the screening visit
- •6.3. A male sexual partner who agrees to use a male condom with spermicide
- •6.4. A sterile sexual partner
- •7. Women of non-child-bearing potential or in post-menopausal status for =1 year
排除标准
- •1. Electrocardiogram (ECG) 12-lead (supine position) with clinically significant abnormalities at screening
- •2. Clinically significant abnormal physical findings that could interfere with the objectives of the study
- •3. Clinically significant abnormal laboratory values at screening indicative of physical illness, or suggesting the subject’s exclusion is in their best interest
- •4. Ascertained or presumptive hypersensitivity to the active principles and/or formulations' ingredients, or history of anaphylaxis to drugs or allergic reactions in general, which the Investigator considers may affect the outcome of the study
- •5. Significant history, in the opinion of the Investigator, of renal, hepatic, gastrointestinal, cardiovascular (in particular history of superficial thrombophlebitis or deep vein thrombosis), respiratory, skin, hematological, endocrine, or neurological diseases that may interfere with the aim of the study
- •6. Taking medications, including over the counter (OTC) medications and herbal remedies, other than hormonal contraceptives for women in the 2 weeks before the first visit of the study
- •7. Use of an inducer or inhibitor of CYP3A4 enzymes (drugs, food, herbal remedies) in the 28 days (part A) or in the 7 days (part B) before the planned first study drug administration, and during the whole study period
- •8. Participation in the evaluation of any investigational product in the 3 months (calculated as the time between the first calendar day of the month that follows the last visit of the previous study and the first visit of the present study) before the first visit of this study
- •9. Blood donations or significant blood loss in the 3 months before the first visit of this study
- •10. History of drug, alcohol (>1 drink/day for women and >2 drinks/day for men, defined according to the USDA Dietary Guidelines 2015-2020), caffeine (>5 cups coffee/tea/day), or tobacco abuse (=10 cigarettes/day)
- •11. Positive result at the urine drug screening test at screening or Day -1
- •12. Positive alcohol breath test at Day -1
- •13. Vegetarian or abnormal diets (<1600 or >3500 kcal/day), or substantial changes in eating habits in the 4 weeks before screening
- •14. Pregnancy, breastfeeding, or positive or missing pregnancy test at screening or Day -1
- •15. Enrolment in a previous study of netupitant or fosnetupitant (alone or in combination with palonosetron)
研究者
相似试验
已完成
1 期
Study to Compare the Pharmacokinetics of Tricaprilin Formulations and a Placebo on Ketone Body ProductionAlzheimer DiseaseNCT03971123Cerecin32
进行中（未招募）
1 期
A study to evaluate the effect of highly reduced kidney function on the processing of fenebrutinib in the bodyISRCTN41455091Genentech, Inc16
已完成
1 期
Mass Balance and Pharmacokinetics Study of Derazantinib in Healthy Male SubjectsHealthy VolunteersNCT04098692Basilea Pharmaceutica12
进行中（未招募）
1 期
A study to evaluate how inavolisib is processed in the body of participants with moderate and highly reduced kidney functioISRCTN11899726F. Hoffmann-La Roche Ltd32
尚未招募
1 期
A Study to Evaluate the Mass Balance of [14C] SY-5007 in Healthy Adult Male Subjects in ChinaHealthy SubjectsNCT06352190Shouyao Holdings (Beijing) Co. LTD8